🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Benitec Biopharma Ltd ADR (BNTC)

NASDAQ
Currency in USD
10.320
-0.480(-4.44%)
Closed
After Hours
10.300-0.020(-0.194%)
BNTC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
10.31010.800
52 wk Range
2.69012.890
Prev. Close
10.32
Open
10.7
Day's Range
10.31-10.8
52 wk Range
2.69-12.89
Volume
30,950
Average Volume (3m)
29,002
1-Year Change
171.58%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
BNTC Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
35.775
Upside
+246.657%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Benitec Biopharma Ltd ADR Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.

InvestingPro Research for Benitec Biopharma Ltd ADR


Promising OPMD Therapy
Benitec's BB-301 shows potential for disease modification in OPMD, with encouraging results from the first treated patient at the six-month mark
Clinical Trial Progress
Explore Benitec's ongoing BB-301 trial, including successful dosing of a second patient and plans for a third, with significant data expected in Q1 2025
Financial Outlook
Benitec's $40 million private placement extends cash runway through 2025, supporting continued clinical development. Analyst price target: $16.00
Market Opportunity
Delve into Benitec's potential to capture a significant share of the OPMD treatment market, with BB-301 positioned as a possible first-in-class therapy
Read full SWOT analysis

Compare BNTC to Peers and Sector

Metrics to compare
BNTC
Peers
Sector
Relationship
P/E Ratio
−9.1x−2.5x−0.6x
PEG Ratio
−0.160.040.00
Price/Book
4.3x3.0x2.6x
Price / LTM Sales
-0.7x3.2x
Upside (Analyst Target)
81.8%138.1%46.3%
Fair Value Upside
Unlock18.4%6.1%Unlock

People Also Watch

1.190
LXRX
-1.66%
20.390
SMMT
+2.15%
104.93
CHRW
+2.22%

FAQ

What Is the Benitec Biopharma ADR (BNTC) Stock Price Today?

The Benitec Biopharma ADR stock price today is 10.32

What Stock Exchange Does Benitec Biopharma ADR Trade On?

Benitec Biopharma ADR is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Benitec Biopharma ADR?

The stock symbol for Benitec Biopharma ADR is "BNTC."

What Is the Benitec Biopharma ADR Market Cap?

As of today, Benitec Biopharma ADR market cap is 204.49M.

What is Benitec Biopharma ADR Earnings Per Share?

The Benitec Biopharma ADR EPS is -5.51.

From a Technical Analysis Perspective, Is BNTC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.